Calcitrene (Page 2 of 2)

ADVERSE REACTIONS

In controlled clinical trials, the most frequent adverse reactions reported for calcipotriene were burning, itching and skin irritation, which occurred in approximately 10-15% of patients. Erythema, dry skin, peeling, rash, dermatitis, worsening of psoriasis including development of facial/scalp psoriasis were reported in 1 to 10% of patients. Other experiences reported in less than 1% of patients included skin atrophy, hyperpigmentation, hypercalcemia, and folliculitis. Once daily dosing has not been shown to be superior in safety to twice daily dosing.

OVERDOSAGE

Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of Calcitrene® (calcipotriene) ointment, 0.005%.

DOSAGE AND ADMINISTRATION

Apply a thin layer of Calcitrene® (calcipotriene) ointment, 0.005% once or twice daily and rub in gently and completely.

HOW SUPPLIED

Calcitrene® (calcipotriene) ointment, 0.005% is available in:

60 gram aluminum tube NDC (51672-5278-3)
120 gram aluminum tube NDC (51672-5278-4)

STORAGE

Store at controlled room temperature 15°C-25°C (59°F-77°F). Do not freeze.

Manufactured by:
Glenmark Generics Ltd.
Colvale-Bardez, Goa 403 513, India

Distributed by:
TaroPharma a division of Taro Pharmaceuticals U.S.A., Inc.
Hawthorne, NY 10532

TaroPharma® and Calcitrene® are trademarks of Taro Pharmaceuticals U.S.A., Inc and/or its affiliates.

November 2011

PPE150010710-1

PRINCIPAL DISPLAY PANEL — 120 g Tube Carton

NDC 51672-5278-4

120 g

Calcitrene®
Calcipotriene Ointment 0.005%

Rx only

TaroPharma ®

FOR TOPICAL DERMATOLIGIC USE ONLY. NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE.

Keep this and all medications out of the reach of children.

TaroPharma ®

Principal Display Panel -- 120 g Tube Carton
(click image for full-size original)
CALCITRENE
calcipotriene ointment
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:51672-5278
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Calcipotriene (Calcipotriene) Calcipotriene 0.05 mg in 1 g
Inactive Ingredients
Ingredient Name Strength
sodium phosphate, dibasic, dihydrate
edetate disodium
mineral oil
petrolatum
propylene glycol
.alpha.-tocopherol
steareth-2
water
Product Characteristics
Color WHITE Score
Shape Size
Flavor Imprint Code
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:51672-5278-5 10 TUBE in 1 CARTON contains a TUBE
1 5 g in 1 TUBE This package is contained within the CARTON (51672-5278-5)
2 NDC:51672-5278-3 1 TUBE in 1 CARTON contains a TUBE
2 60 g in 1 TUBE This package is contained within the CARTON (51672-5278-3)
3 NDC:51672-5278-4 1 TUBE in 1 CARTON contains a TUBE
3 120 g in 1 TUBE This package is contained within the CARTON (51672-5278-4)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA090633 03/24/2010
Labeler — Taro Pharmaceuticals U.S.A., Inc. (145186370)
Establishment
Name Address ID/FEI Operations
Glenmark Generics Ltd. 677318665 MANUFACTURE (51672-5278)

Revised: 01/2019 Taro Pharmaceuticals U.S.A., Inc.

Page 2 of 2 1 2

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.